EN DE
Watch Xuanzhu Biopharm Co Ltd for free: once a week we email you where price and fair value stand.
Data-driven stock valuation

Xuanzhu Biopharm Co Ltd (2575) fair value: what the stock is really worth

As of Nov 18, 2026: fair value (intrinsic value) of Xuanzhu Biopharm Co Ltd stock HK$1.42, price HK$7.70, that is 81.6% below the price, quality 56 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare HK · Based in China

XB Xuanzhu Biopharm Co Ltd logo Thin data Nov 19, 2026

Xuanzhu Biopharm Co Ltd

2575 · HK

Far too expensive (fair value 82% below the price) and falling price, but solid company: meets 1 of 3 rules.

Follow free in the weekly email
Quality 56/100 
Expensive Growth (revenue YoY +72.1 %/yr in CNY) 
Fair value HK$1.42 · Strongly overvalued 
Falling price (downtrend) 
Negative free cash flow 
Trails peers (2/8) 
Narrow moat 9/100 · thin data
Thin data 
⚠ Small free float
Watch Xuanzhu Biopharm Co Ltd for free: once a week we email you where price and fair value stand. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

HK$82.95 HK$7.70 Fair Value HK$1.42 Oct 2025 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 19, 2026.

How to read this chart

13‑month range HK$7.70 – HK$82.95 · fair‑value band HK$0.9400 – HK$1.78 · the HK$7.70 price screens above the HK$1.42 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 19, 2026.

Follow Xuanzhu Biopharm Co in your weekly email

Every Wednesday you see whether Xuanzhu Biopharm Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Xuanzhu Biopharmaceutical Co., Ltd. engages in the development, industrialization, and commercialization of small-molecule chemical drugs and macromolecular biopharmaceuticals in China.

Show moreShow less

Its lead product candidates include Core- KBP-3571 for the treatment of duodenum ulcers; XZP-3287, a CDK4/6 inhibitor for the treatment of HR+/HER2 advanced breast cancer; and XZP-3621, a first-line treatment for patients with anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer.

The company also develops KM501, a first-in-class HER2/HER2 bispecific antibody drug conjugate, which is in Phase I clinical trial; KM602, which is in Phase I clinical trial for anti-tumor; XZP-7797, a selective and brain-penetrating poly ADP-ribose polymerase 1 inhibitor; and XZP-6924, a ubiquitin-specific protease 1 (USP1) inhibitor.

In addition, it develops XZB-0004, an oral small molecule anexelekto inhibitor; XZP-6877, a DNA-dependent protein kinase inhibitor; NG-350A, a next-generation oncolytic viral therapy; XZP-5610, a non-steroid farnesoid X receptor; and XZP-6019, a first-in-class ketohexokinase (KHK) inhibitor.

The company was founded in 2008 and is headquartered in Beijing, China. Xuanzhu Biopharmaceutical Co., Ltd. is a former subsidiary of Sihuan Pharmaceutical Holdings Group Ltd.

Stock analysis

Xuanzhu Biopharm Co Ltd (2575) currently trades at HK$7.70, while our model-based Fair Value estimate is HK$1.42, 82% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 88/100, which puts the data coverage at low.

Scenario range: HK$0.9400 (bear) to HK$1.78 (bull), the price of HK$7.70 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 56/100 (solid quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Xuanzhu Biopharm Co Ltd reported revenue of 56.1M CNY in FY2025 versus 32.0K CNY in FY2023, a compound +4,085.9%/yr. Reported net income was −266M CNY in FY2025.

Key figures

Market cap HK$4.0B (≈ $512M) Small · P/S ratio 43.4 · EPS (TTM) HK$−0.2500 · Return on equity −19.6% · Return on assets (EBIT) −29.6% (5-year average) · Operating margin −114% · Revenue (TTM) 103M CNY · Revenue growth (YoY) +288%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (low confidence).

What moves the price

The share trades about 91% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −82%, 2575 screens richer than that median.

Fair Value models

Bear HK$0.9400 Fair Value HK$1.42 Bull HK$1.78
Price HK$7.70 · Downside -81.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) HK$0.9400 HK$1.42 HK$1.78 52
All 1 models by family
Asset-Based
NCAV (Graham) HK$0.9400 HK$1.42 HK$1.78 52

Open the full fair value analysis →

Quality Score breakdown

Overall quality 56/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 91
Are margins and returns getting better?
Cashflow 8
Do the profits arrive as real cash?
Financial strength 100
Debt, balance sheet and risk of trouble
Investment 93
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 3
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

2575 screens overvalued: fair value 82% below the price. Compare with Merck KGaA →

Compare Xuanzhu Biopharm Co Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 608 stocks

Beats the industry median on 2/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 56 · Above median
Fair Value upside −81.6% · Bottom 25%
Profitability
Return on assets −14.6% · Bottom 25%
Operating margin (12 months) −113.6% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 288.1% · Top 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 2.23× · Pricier than median
P/S (12 months) 32.97× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 20
FUTURE (revenue growth)100 · sector 29
PAST (return on equity)0 · sector 26
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 32

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $85.57 $113.53 +33% vs 2575
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥46.90 ¥52.43 +12% vs 2575
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,872 ₹1,983 +6% vs 2575
Haleon plc HLN $9.08 $8.47 −7% vs 2575
Merck KGaA MRK €149.50 €108.83 −27% vs 2575
Galderma Group GALD CHF 187.55 CHF 112.46 −40% vs 2575
Takeda Pharmaceutical Company TAK $21.27 $11.23 −47% vs 2575
Sandoz Group SDZ CHF 81.50 CHF 41.06 −50% vs 2575
Teva Pharmaceutical Industries Limited TEVA $42.23 $20.74 −51% vs 2575
Divi's Laboratories Limited DIVISLAB ₹11,049 ₹1,567 −86% vs 2575

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Xuanzhu Biopharm Co Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Xuanzhu Biopharm Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/2575

Frequently asked questions

Is Xuanzhu Biopharm Co Ltd (2575) overvalued or undervalued?
As of Nov 19, 2026, our model estimates a fair value of HK$1.42 versus a price of HK$7.70, about 82% lower (overvalued).
What is the fair value of 2575?
Our model-based fair value for Xuanzhu Biopharm Co Ltd is HK$1.42 (as of Nov 19, 2026), built from audited fundamentals. The current price: HK$7.70.
What is the quality score of 2575?
Xuanzhu Biopharm Co Ltd has a Quality Score of 56/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Xuanzhu Biopharm Co Ltd (2575)?
Our model-based price target is the fair value of HK$1.42 (as of Nov 19, 2026) from 1 valuation models. Cautious scenario HK$0.9400, optimistic scenario HK$1.78. It is a calculation from audited fundamentals, not an analyst target.
What is the Xuanzhu Biopharm Co Ltd stock forecast for 2026?
Our models put fair value at HK$1.42, about 82% lower versus a price of HK$7.70 (overvalued). Cautious scenario HK$0.9400, optimistic scenario HK$1.78. The calculation is refreshed regularly with new filings.
What is the revenue of Xuanzhu Biopharm Co Ltd (2575)?
Xuanzhu Biopharm Co Ltd reported trailing-twelve-month revenue of about 103M CNY (latest available figure, as of Nov 19, 2026).
What is the intrinsic value of Xuanzhu Biopharm Co Ltd (2575)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Xuanzhu Biopharm Co Ltd it is HK$1.42 per share (as of Nov 19, 2026), against a price of HK$7.70. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Xuanzhu Biopharm Co Ltd stock overvalued or undervalued in 2026?
As of Nov 19, 2026, 2575 trades above its calculated fair value: price HK$7.70, fair value HK$1.42, a gap of about −82% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 2575?
No. The price is what the market pays today (HK$7.70); the fair value is what the company's own numbers justify (HK$1.42). For Xuanzhu Biopharm Co Ltd the two are HK$6.28 per share apart. That gap is exactly why we show both numbers side by side.
How much is Xuanzhu Biopharm Co Ltd worth?
The market values Xuanzhu Biopharm Co Ltd at about HK$4.0B (market capitalisation, as of Nov 19, 2026). Per share that is HK$7.70; our models calculate a fair value of HK$1.42 per share.
What do the bullish and bearish scenarios say about 2575?
Our models span a range for Xuanzhu Biopharm Co Ltd: cautious scenario HK$0.9400, base HK$1.42, optimistic HK$1.78 per share (as of Nov 19, 2026, price HK$7.70). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Xuanzhu Biopharm Co Ltd (2575)?
Balance-sheet figures for Xuanzhu Biopharm Co Ltd (as of Nov 19, 2026): return on equity −19.6%. They feed the Quality Score of 56/100, which measures business quality independently of the share price.
How far is 2575 from its 52-week high?
Xuanzhu Biopharm Co Ltd trades at HK$7.70, about 91% below its 52-week high of HK$82.95 and at the low of HK$7.70 (as of Nov 18, 2026). Distance from the high says nothing about value: that is what the fair value of HK$1.42 is for.
Which stocks are comparable to Xuanzhu Biopharm Co Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Xuanzhu Biopharm Co Ltd stock attractive at the current price?
The data as of Nov 19, 2026: price HK$7.70, calculated fair value HK$1.42 (−82%), Quality Score 56/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 2575 calculated?
We run Xuanzhu Biopharm Co Ltd through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of HK$1.42 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 12.0% above its aggregate fair value. Xuanzhu Biopharm Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Xuanzhu Biopharm Co Ltd (2575)?
The closing price on Nov 18, 2026 was HK$7.70. Our model-based fair value is HK$1.42, about 82% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Xuanzhu Biopharm Co Ltd right now?
The price sits above even our optimistic bull case (HK$1.78). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (56/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (HK$0.9400 to HK$1.78) leaves room in how you read the outcome.

Key figures of Xuanzhu Biopharm Co Ltd

How large is the market capitalisation of Xuanzhu Biopharm Co Ltd (2575)?
The market capitalisation of Xuanzhu Biopharm Co Ltd is HK$4.0B (≈ $512M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Xuanzhu Biopharm Co Ltd (2575)?
The price-to-sales ratio of Xuanzhu Biopharm Co Ltd is 43.4 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Xuanzhu Biopharm Co Ltd (2575)?
Earnings per share at Xuanzhu Biopharm Co Ltd are HK$−0.2500. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Xuanzhu Biopharm Co Ltd (2575)?
The return on equity (ROE) of Xuanzhu Biopharm Co Ltd is −19.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Xuanzhu Biopharm Co Ltd (2575)?
On an EBIT basis the return on assets of Xuanzhu Biopharm Co Ltd is −29.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Xuanzhu Biopharm Co Ltd (2575)?
The operating margin of Xuanzhu Biopharm Co Ltd is −114% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Xuanzhu Biopharm Co Ltd (2575)?
Revenue at Xuanzhu Biopharm Co Ltd is growing 288% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Xuanzhu Biopharm Co Ltd (2575) generate?
The free cash flow of Xuanzhu Biopharm Co Ltd is −224M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Xuanzhu Biopharm Co Ltd (2575) hold?
Xuanzhu Biopharm Co Ltd holds more cash than debt, 587M CNY net (balance sheet 30 Jun 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Xuanzhu Biopharm Co Ltd in the live analysis

One click puts Xuanzhu Biopharm Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.